) BV, respectively, were: EDN 15.6% and 43.8%; pCalprotectin 24.5% and 55.0%; and suPAR 5.7% and 20.0%. Low indices of individuality were observed for all measurands, indicating the need for RCVs to guide clinical interpretation. This study is the first to report BV estimates with accompanying APS, II and RCV for EDN, suPAR and pCalprotectin.
No takes yet. Share an insight, caveat, or question.
Stolberg et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: